EyeControl Company
"Wearable Assistive Communication Device."
EyeControl is an assistive technology for intensive care units. The device uses pupil movements to enable bi-directional remote communication between ventilated patients and medical staff, thereby improving accuracy of care, freeing up beds and equipment, and limiting contagion by reducing the need for proximity. EyeControl has two target markets: medical facilities for ventilated patients and home care for locked-in individuals.
EyeControl will pilot the medical device at hospitals treating patients with COVID-19, where it can help preserve lines of communication between ventilated patients and nurse stations outside quarantine.
EyeControl is CE marked, FDA listed, and ISO certified. The company concluded a clinical trial in the intensive care unit at the Tel Aviv Sourasky Medical Center and is scheduled to conduct an expanded trial at Emory University Hospital.
In 2019, commercialization of the EyeControl home care device commenced in Israel and the United Kingdom. The device is reimbursed by the Israel Ministry of Health, UK National Health Service, and U.S. Centers for Medicare and Medicaid Services.
Combating Coronavirus Pandemic:
EyeControl's solution helps address the Coronavirus Pandemic.
EyeControl is an assistive technology for intensive care units. The device uses pupil movements to enable bi-directional remote communication between ventilated patients and medical staff, thereby improving accuracy of care, freeing up beds and equipment, and limiting contagion by reducing the need for proximity. EyeControl has two target markets: medical facilities for ventilated patients and home care for locked-in individuals.
EyeControl will pilot the medical device at hospitals treating patients with COVID-19, where it can help preserve lines of communication between ventilated patients and nurse stations outside quarantine.
EyeControl is CE marked, FDA listed, and ISO certified. The company concluded a clinical trial in the intensive care unit at the Tel Aviv Sourasky Medical Center and is scheduled to conduct an expanded trial at Emory University Hospital.
In 2019, commercialization of the EyeControl home care device commenced in Israel and the United Kingdom. The device is reimbursed by the Israel Ministry of Health, UK National Health Service, and U.S. Centers for Medicare and Medicaid Services.
Combating Coronavirus Pandemic:
EyeControl's solution helps address the Coronavirus Pandemic.
.png)
.png)
.png)
(Reupload).png)
(Reupload).png)
Technology:
Others
Industry:
HealthTech
Headquarters:
Israel
Founded Date:
7-8
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership